Amylin Pharmaceuticals, a wholly owned subsidiary of Bristol- Myers Squibb, is an exceptional company of extraordinary people. Their willingness to challenge conventional thinking as much as they challenge themselves, their resolve, resiliency and passion for the patient are improving the lives of millions. The men and women of Amylin are discovering, developing, and bringing to market innovative therapies with life-changing potential for people struggling with diabetes and obesity—merging epidemics that are fast becoming the major health crises of our lifetime. In the process, they are building an exciting new franchise in the treatment of metabolic disease and a pipeline of possibilities for future healthcare solutions.